Viracta Therapeutics, Inc. VIRX
Set alert
At close · Jul 2
After hours · Jul 2, 4:00 PM ET
- YTD
- -93.92%
- 1 year
- -93.89%
- Open
- 0.00978
- Prev close
- 0.00978
- Mkt cap
- 9.25M
- Vol
- 0
- Avg vol
- 2.19M
- EPS
- -1.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.00978
- High
- 0.00978
- Forward P/E
- -0.38
- Beta
- 0.30
- Short ratio
- 1.85
- Inst. own
- 50.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.1908
- 200-d avg
- 0.49815
- 1y target
- 3.00
News
1 year ago globenewswire.com
Viracta Therapeutics Announces Wind Down of Operations
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday
-
1 year ago benzinga.com
Why Evaxion Biotech Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
Why Evaxion Biotech Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
1 year ago globenewswire.com
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
1 year ago globenewswire.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) -
2 years ago zacks.com
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now
Sunesis (VIRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall…
2 years ago investorplace.com
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX…
2 years ago globenewswire.com
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial…
2 years ago globenewswire.com
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's…
2 years ago globenewswire.com
Viracta Therapeutics Announces New Employment Inducement Grants
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
2 years ago globenewswire.com
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
2 years ago globenewswire.com
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell…
2 years ago investorplace.com
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
There are speculative ideas and then there are penny stocks under $1. Outside of forex trading or high-risk options trades, it generally doesn't get much more treacherous than this space.
2 years ago globenewswire.com
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
-
2 years ago benzinga.com
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
2 years ago globenewswire.com
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete…
2 years ago globenewswire.com
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy…
-
2 years ago benzinga.com
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
2 years ago globenewswire.com
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supporting its speed to market strategy; topline results from…
2 years ago globenewswire.com
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of…
2 years ago globenewswire.com
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
2 years ago globenewswire.com
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated…
2 years ago globenewswire.com
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
First orphan drug designation for Nana-val granted in EBV + solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) --…
2 years ago globenewswire.com
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 369 companies hit new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 100 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 345 companies set new 52-week lows.
-
3 years ago benzinga.com
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 127 companies set new 52-week lows.
-
4 years ago benzinga.com
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies reached new 52-week lows.
-
4 years ago benzinga.com
68 Biggest Movers From Yesterday
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions.
-
4 years ago benzinga.com
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows.
-
4 years ago benzinga.com
63 Biggest Movers From Yesterday
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
-
4 years ago benzinga.com
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
-
5 years ago benzinga.com
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
-
5 years ago benzinga.com
56 Biggest Movers From Yesterday
Gainers Bridgford Foods Corporation (NASDAQ: BRID) shares surged 46.2% to close at $20.74 on Tuesday.
-
5 years ago benzinga.com
70 Biggest Movers From Yesterday
Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash.